Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings DexCom, Inc.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Highlights: DexCom, Inc.
  • The company's profit outlook over the next few years is a strong asset.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: DexCom, Inc.
  • With a 2026 P/E ratio at 33.97 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.

Rating Financials

DexCom, Inc. SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

DexCom, Inc. SectorUnited States

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

DexCom, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

DexCom, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

DexCom, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
31.98B
BBB
187B
BBB
112B
BBB
61.15B
AA
54.39B
AAA
48.17B
A
30.91B
A
24.92B
AA
23.15B
AAA
-
22.2B
AA
Average 59.5B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. DXCM Stock
  4. Ratings DexCom, Inc.